Sekeres MA, Zeidan AM, Santini V, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcárcel D, Regnault A, Creel K, Sun L, Wan Y, Navada S, Berry T, Feller F, Platzbecker U, Díez-Campelo M, Oliva EN. Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study. haematol [Internet]. 2020Sep.10 [cited 2026Feb.6];. Available from: https://haematologica.org/article/view/13107